ATE374190T1 - Tetrahydrochinazolinderivate als cfr-antagonisten - Google Patents

Tetrahydrochinazolinderivate als cfr-antagonisten

Info

Publication number
ATE374190T1
ATE374190T1 AT04763724T AT04763724T ATE374190T1 AT E374190 T1 ATE374190 T1 AT E374190T1 AT 04763724 T AT04763724 T AT 04763724T AT 04763724 T AT04763724 T AT 04763724T AT E374190 T1 ATE374190 T1 AT E374190T1
Authority
AT
Austria
Prior art keywords
sup
cfr
antagonists
tetrahydroquinazoline
derivatives
Prior art date
Application number
AT04763724T
Other languages
English (en)
Inventor
Robin Clark
Richard Cournoyer
Counde O'yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE374190T1 publication Critical patent/ATE374190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04763724T 2003-08-12 2004-08-03 Tetrahydrochinazolinderivate als cfr-antagonisten ATE374190T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49451103P 2003-08-12 2003-08-12

Publications (1)

Publication Number Publication Date
ATE374190T1 true ATE374190T1 (de) 2007-10-15

Family

ID=34135343

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04763724T ATE374190T1 (de) 2003-08-12 2004-08-03 Tetrahydrochinazolinderivate als cfr-antagonisten

Country Status (9)

Country Link
US (1) US7223767B2 (de)
EP (1) EP1656354B1 (de)
JP (1) JP2007501821A (de)
CN (1) CN100398524C (de)
AT (1) ATE374190T1 (de)
CA (1) CA2534785A1 (de)
DE (1) DE602004009200T2 (de)
ES (1) ES2293317T3 (de)
WO (1) WO2005014557A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CN101511842B (zh) 2006-07-06 2012-10-31 阵列生物制药公司 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
WO2008006032A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
SI2173723T1 (sl) * 2007-07-05 2011-12-30 Array Biopharma Inc Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2240455B1 (de) * 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylierte pyrimidyl-cyclopentane als akt-proteinkinasehemmer
JP5346345B2 (ja) * 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
US8741259B2 (en) * 2008-10-20 2014-06-03 Marvin C. Gershengorn Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP2563777A4 (de) 2010-04-08 2013-09-04 Us Health Inverse agonisten und neutrale agonisten für den tsh-rezeptor
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
KR20140022053A (ko) 2011-04-01 2014-02-21 제넨테크, 인크. Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
WO2014034898A1 (ja) 2012-08-30 2014-03-06 日本新薬株式会社 ピリジン誘導体及び医薬
CN104262265B (zh) * 2014-07-21 2016-04-13 湖南华腾制药有限公司 一种四氢喹唑啉衍生物的制备方法
CN106083554B (zh) * 2016-06-12 2018-12-07 南京工业大学 一种一锅法制备2-乙酰基环己酮的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203072A (en) * 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
JPS6270A (ja) * 1985-03-07 1987-01-06 Sankyo Co Ltd シクロペンタ〔ｄ〕ピリミジン誘導体
US5234936A (en) * 1991-10-24 1993-08-10 American Home Products Corporation Pyrimidocycloalkanes as a ii antagonists
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
ES2207834T3 (es) * 1997-04-22 2004-06-01 Janssen Pharmaceutica N.V. Quino- y quinazolinas antagonistas del crf.
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
WO2002088095A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)

Also Published As

Publication number Publication date
CA2534785A1 (en) 2005-02-17
ES2293317T3 (es) 2008-03-16
EP1656354B1 (de) 2007-09-26
US20050038052A1 (en) 2005-02-17
JP2007501821A (ja) 2007-02-01
WO2005014557A1 (en) 2005-02-17
CN1835931A (zh) 2006-09-20
CN100398524C (zh) 2008-07-02
EP1656354A1 (de) 2006-05-17
DE602004009200D1 (de) 2007-11-08
DE602004009200T2 (de) 2008-07-10
US7223767B2 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
DK1606242T3 (da) Azidfri fremgangsmåde til fremstilling af 1,2-diaminoforbindelser
ATE469892T1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
ATE413388T1 (de) Muskarin antagonisten
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
MY136824A (en) Substituted benzoxazinones and uses thereof
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
MY138826A (en) 2,7-substituted indoles
MXPA05009523A (es) Derivados de quinolina/benzoxazinona y sus usos.
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
MXPA05009282A (es) Derivados de anilina sustituidos.
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
BR0211140A (pt) Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht
DE602005007064D1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties